Department of Anesthesiology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Molecules. 2018 Jan 26;23(2):245. doi: 10.3390/molecules23020245.
Traumatic brain injury (TBI) is one of the most frequent causes of combat casualties in Operations Iraqi Freedom (OIF), Enduring Freedom (OEF), and New Dawn (OND). Although less common than combat-related blast exposure, there have been significant numbers of blast injuries in civilian populations in the United States. Current United States Department of Defense (DoD) ICD-9 derived diagnoses of TBI in the DoD Health Care System show that, for 2016, severe and moderate TBIs accounted for just 0.7% and 12.9%, respectively, of the total of 13,634 brain injuries, while mild TBIs (mTBIs) accounted for 86% of the total. Although there is a report that there are differences in the frequency of long-term complications in mTBI between blast and non-blast TBIs, clinical presentation is classified by severity score rather than mechanism because severity scoring is associated with prognosis in clinical practice. Blast TBI (bTBI) is unique in its pathology and mechanism, but there is no treatment specific for bTBIs-these patients are treated similarly to TBIs in general and therapy is tailored on an individual basis. Currently there is no neuroprotective drug recommended by the clinical guidelines based on evidence.
创伤性脑损伤(TBI)是伊拉克自由行动(OIF)、持久自由行动(OEF)和新黎明行动(OND)中战斗伤亡的最常见原因之一。尽管与战斗相关的爆炸暴露较少,但在美国平民中也有大量的爆炸伤害。目前美国国防部(DoD)基于 ICD-9 的 DoD 医疗保健系统中的 TBI 诊断显示,2016 年,严重和中度 TBI 分别仅占总 13634 例脑损伤的 0.7%和 12.9%,而轻度 TBI(mTBI)占总损伤的 86%。尽管有报道称,在 mTBI 与非爆炸 TBI 之间,长期并发症的频率存在差异,但临床表现是根据严重程度评分进行分类的,而不是根据机制,因为严重程度评分与临床实践中的预后相关。爆炸性 TBI(bTBI)在其病理和机制上是独特的,但没有专门针对 bTBI 的治疗方法——这些患者的治疗与一般 TBI 相似,治疗方案是根据个体情况制定的。目前,基于证据,临床指南没有推荐任何神经保护药物。